DailyTimeCapsule brief
March 14, 2013
On March 14, 2013, the political landscape in the United States saw a significant moment with the emergence of a conservative figure emphasizing a common touch. This day marked discussions around a spinoff of Time Inc., which rattled employees within the company, hinting at uncertainties in the media sector. In healthcare news, the FDA announced plans to loosen regulations on the approval of Alzheimer's drugs, signaling a shift in policy that could affect countless families dealing with the disease. Concurrently, the international stage remained tense, with various global issues unfolding, yet the focus in America was largely on domestic policy changes and their implications for citizens.
Key developments
-
In March 2013, Jorge Mario Bergoglio was elected as Pope Francis, marking a historic moment as the first Jesuit and the first Latin American pope in history. While he brings a fresh perspective to the papacy, his conservative views, particularly on issues such as gay marriage and abortion, suggest that his leadership may not veer far from traditional Catholic doctrine. Pope Francis's appointment was seen as a signal of the Church's focus on addressing social justice issues and engaging with the world, despite his conservative stances.
Wikimedia Current Events -
The separation of Time Inc. from Time Warner marked a significant shift in the media landscape, as it stripped Time Inc. of its valuable film and television assets. This division raised concerns among employees, who anticipated the potential instability and operational challenges that could follow the loss of such propelling resources. Employees feared job security and questioned the future direction of the company without the backing of its more lucrative parent assets.
Wikimedia Current Events -
The FDA has proposed changes to the approval process for Alzheimer’s drugs, indicating that improvements in memory or reasoning tests could suffice for drug approval, even if daily functioning remains unchanged. This shift aims to accelerate the availability of new treatments amidst a pressing need for effective therapies, given the rising prevalence of Alzheimer’s disease. By focusing on cognitive improvements rather than overall daily living abilities, the FDA hopes to open doors for innovative drugs that may contribute to patient care.
Wikimedia Current Events
